Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - General

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Revenue projections:

Revenue projections for ABBV
Revenue projections for ABBV

AbbVie Inc.'s revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.

Financial Ratios:

currentRatio 0.67100
forwardPE 12.65811
debtToEquity 0.00000
earningsGrowth 0.00000
revenueGrowth 0.10000
grossMargins 0.71620
operatingMargins 0.34108
trailingEps 2.36000
forwardEps 16.09324

ABBV's current ratio being 0.671 highlights potential liquidity concerns, as the company may not have enough cash reserves and assets to cover short-term debts. This raises questions about how ABBV will meet its immediate financial obligations.
AbbVie Inc.'s Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
AbbVie Inc.'s positive gross and operating margins indicate the company's ability to operate profitably. These margins reflect strong financial management, with efficient cost control contributing to sustained profitability and a solid financial outlook.
ABBV's forward EPS being higher than its trailing EPS points to expected growth in profitability. This suggests that the company is projected to perform better in the current financial year, with higher earnings forecasted compared to the previous year.

Price projections:

Price projections for ABBV
Price projections for ABBV

AbbVie Inc.'s price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in AbbVie Inc.'s ability to achieve strong financial results.

Insider Transactions:

Insider Transactions for ABBV
Insider Transactions for ABBV


8 ABBV sales were executed, with market price at 207.59625053405762.There were no sell transactions recorded during the period under consideration.AbbVie Inc.'s current price levels are seeing more buying activity than selling, which might indicate a bullish sentiment. Investors appear to be confident, interpreting the buying trend as a sign of positive expectations for the stock's future performance.

Recommendation changes over time:

Recommendations trend for ABBV
Recommendations trend for ABBV


The recent buy bias for ABBV from analysts signals strong confidence in the stock's potential. This positive sentiment could encourage investors to see ABBV as a smart place to invest their money, especially those looking for stable, long-term returns in a well-established company.